OPPSCIENCE
OPPSCIENCE, a leader in Intelligence Analysis Management (IAM), reaffirms its support for public security by sponsoring the AGIR event. Following the introduction of its latest version of SPECTRA, a software dedicated to law enforcement, during Milipol Paris, OPPSCIENCE contributes to accelerating the initiatives of the National Gendarmerie on the seek of innovations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129543708/en/
The encounters at AGIR supported by OPPSCIENCE (Photo: Business Wire)
MEETINGS AT AGIR: UNDERSTANDING THE NEEDS OF THE GENDARMERIE FOR LAW ENFORCEMENT
Strengthening the dialogue between law enforcement and the technology industry is the goal of the AGIR exhibition (Accompagnement par la Gendarmerie de l’Innovation, de l’Industrie et de la Recherche). Initiated by the innovation unit of the National Gendarmerie, this exhibition enables innovators in the Gendarmerie community, specialized units, project directors, and other innovative industries to meet and exchange ideas. AGIR took place on November 28th at Station F, in Paris, allowing participants to understand the current and future needs of the Gendarmerie in crime-fighting and security enhancement.
SPECTRA SOFTWARE: EQUIPPING LAW ENFORCEMENT WITH CUTTING-EDGE TECHNOLOGIES FOR CRIMINAL INVESTIGATION
Supporting law enforcement by providing tailored and high-performing solutions is among OPPSCIENCE's missions. Indeed, its software allows massive data analysis and processing for law enforcement under security. SPECTRA can now be used by French ministry operatives through ANFSI (Agence du numérique des forces de sécurité intérieure). The latter operates under the joint authority of the directors-general of the French National Gendarmerie and the French National Police. It succeeds the ST(SI)² (The French Homeland Security Information Systems and Technologies Department), with which OPPSCIENCE has been collaborating for over a dozen years.
ANFSI chose OPPSCIENCE due to SPECTRA’s advanced capabilities in the analysis of all data types (images, videos, audios, texts) from any source, system, and infrastructure. It highlights relationships between different information to form a comprehensive and contextualized view of known information on a searched subject. It enables investigators to save up to 60% of time by automating data collection, analysis, and contextualization processes. The goal is to make complex and strategic decision-making more efficient, informed, and effective. SPECTRA is GDPR compliant and ensures data security and traceability.
PARTNER WITH THE AGIR MEETINGS TO STRENGTHEN TIES BETWEEN LAW ENFORCEMENT & INNOVATION INDUSTRY
By supporting the 2023 edition of the AGIR meetings alongside GICAT, OPPSCIENCE aims to materialize and accelerate ongoing programs within the National Gendarmerie by presenting innovative technological solutions.
OPPSCIENCE solutions are deployed among thousands of law enforcement agents, including several hundred criminal investigators (OPJ). The software is also used within the Ministry of Armed Forces as part of the Artemis.IA project.
Amid the constant evolution and increasing diversity of digital threats, these technologies offer law enforcement and intelligence services essential flexibility to adapt their methods and optimize their operational actions.
Organized attacks, trafficking, scams, identity manipulations... data related to these cases are scattered across multiple systems. Manually gathering them, extracting key information, and contextualizing them is extremely time-consuming. Without a tool to fully exploit the information contained in existing data, the risk of missing important elements increases. Equipping law enforcement with innovative technologies to assist in their missions is crucial to ensuring their performance. Big Data is a rich source of knowledge, provided we have the solutions to understand it. Finding French solutions to tomorrow's challenges is one of the goals of this event.
ABOUT OPPSCIENCE
OPPSCIENCE is a French software publisher, specialized in Big Data and artificial intelligence. It became a leader in the field of Intelligence Analysis Management by designing technologies to transform scattered and multi-format data into knowledge directly accessible to end-users from a single-entry point. The technologies implemented are derived from the semantic web, knowledge modeling techniques, and natural language processing. OPPSCIENCE solutions are currently deployed to over 300,000 users in France and internationally.
ABOUT AGIR
AGIR is an event organized by the Gendarmerie nationale's innovation unit to accelerate programs, share solutions and discover operational examples. Following the meetings held during AGIR 2021, over €1.5 million in contract have been signed by the Gendarmerie/Governement agencies. Gather the Gendarmerie community of innovators, specialized units, future equipment project managers and industrial partners.
- Strengthen ties/ connections with departmental and interdepartmental authorities and forces.
- Share our needs, support capacity-building initiatives and discover potential solutions.
- Promote, realize and accelerate the current programs by introducing new technical solutions.
- Build an ever-expanding innovation ecosystem!
- Increase dialogue and initiate communications!
WEBSITE
- Website: https://oppscience.com
SOCIAL MEDIAS
- LinkedIn : https://www.linkedin.com/company/oppscience/
- Twitter : https://twitter.com/OppScience
- Instagram : https://www.instagram.com/oppscience
- Facebook : https://www.facebook.com/OPPSCIENCE
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231129543708/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom